ARK Genomic Revolution ETF
ARKG
2 hedge funds and large institutions have $623K invested in ARK Genomic Revolution ETF in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
11.91% less ownership
Funds ownership: 19.62% → 7.71% (-12%)
27% less capital invested
Capital invested by funds: $854K → $623K (-$231K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$244K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$47.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $614K | -$244K | -10,747 | -28% |
|
|
2
UBS Group
Zurich,
Switzerland
| $9K | -$47.7K | -2,102 | -84% |
|
ARKG Hedge Fund Activity: Q1 2015 in Review
2 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2015, worth a combined $623K — down 27% from $854K a quarter earlier.
Fund positioning in ARKG was balanced in Q1 2015: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Jane Street, cutting an estimated $244K.
- 2 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $623K of ARK Genomic Revolution ETF stock for Q1 2015, down 27% quarter-over-quarter.
- 0 funds opened new ARK Genomic Revolution ETF positions in Q1 2015 and 0 closed out.
- The largest ARK Genomic Revolution ETF seller in Q1 2015 was Jane Street, an estimated $244K sold.
Based on aggregated 13F filings for Q1 2015.